Applied UV Enters Three Year Agreement Through its Scandinavian Distribution Partner Airocide Nordic Oy with Plandent Division for Distribution of Airocide to Dental Providers

Applied UV Enters Three Year Agreement Through its Scandinavian Distribution Partner Airocide Nordic Oy with Plandent Division for Distribution of Airocide to Dental Providers

Covers Finland with plans to expand throughout all of countries in Scandinavia and Europe

Applied UV, Inc. (NASDAQCM:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically announces that it's Scandinavian distributor Airocide Nordic Oy has entered into a three-year agreement with Plandent Division for distribution of its patented Airocide® commercial air purification systems to the professional dental community launching initially in Finland, expanding distribution to include all of the countries in Scandinavia and plans to broaden expansion throughout all of Europe

Headquartered in Helsinki, Finland, Plandent Division is a wholly-owned entity of Planmeca Oy, the 3rd largest supplier to the dental industry in Europe. The company operates throughout Europe supplying a wide range of quality-driven, modern dental products and solutions.

"We estimate there are approximately 21,500 dental practices throughout Scandinavia, representing a significant market opportunity for our products," stated Max Munn, President and Interim CEO. "Plandent is a recognized leader for the supply of dental products and equipment and an ideal partner to expand our footprint and helps us capture a meaningful share of the Scandinavian market. In healthcare environments, air quality is perhaps the most easily forgotten component of microbial burden. The constant traffic of patients and staff combined with the effect of ongoing procedures ensures consistently high levels of airborne microbial contamination. Chemicals used in cleaning and sterilization can also contribute to significant levels of VOCs in the air. Implementing the Airocide® air disinfection technology, which constantly works at the point of care, results in increased safety of the environment and the wellbeing of patients and staff."

Mr. Munn continued, "Recent health threats and the possibility of contracting a potentially life-threatening virus such as COVID-19 has increased the dental community's pursuit of solutions that can reduce aerosols and splatter and provide clean air quality. Research published in the Journal of Dentistry in February 2021, confirmed that if a room's ventilation rate is low, respiratory aerosol particles can remain in the indoor air for a long time, making it critical to remove respiratory aerosol to minimize potential exposures of airborne viruses to patients and providers. Creating clean air quality in dental offices is not possible solely with the use of high suction and a central air conditioning system. Improved ventilation and air filtration are important steps in a multi-layered approach for safe delivery of dental care. By installing the patented Airocide® System, both staff and patients will have additional protection."

About Plandent Division

Plandent Division is part of the Planmeca Group, whose parent company Planmeca Oy is the largest privately-owned company in the dental sector. Planmeca Oy, the third largest dental equipment manufacturer in Europe, designs and manufactures advanced dental equipment and x-ray units, software products and imaging solutions. Planmeca exports 98 percent of its production to over 120 countries through 550 distributors. Headquartered in Helsinki, Finland, the Plandent Division operates in nearly 15 countries throughout Europe. Plandent Division's business units supply a wide range of quality-driven, modern dental products and solutions. Since its founding in 1972, Plandent Division has become one of the most influential dental suppliers in Europe. For more information, please visit https://www.planmeca.com/company/planmeca-group/ or https://www.plandent.com/.

About Applied UV

Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide® air purification devices are research backed, clinically proven and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, post-harvest, grocery and homes. For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; https://www.airocide.com https://kesscience.com; https://scientificairmanagement.com and, https://munnworks.com/.

Forward-Looking Statements

The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.

For additional Company Information:

Applied UV Inc.
Max Munn
Applied UV Interim CEO
max.munn@sterilumen.com

Contact:

Brett Maas, Managing Principal
Hayden IR
brett@haydenir.com
(646) 536-7331

SOURCE: Applied UV, Inc.



View source version on accesswire.com:
https://www.accesswire.com/689671/Applied-UV-Enters-Three-Year-Agreement-Through-its-Scandinavian-Distribution-Partner-Airocide-Nordic-Oywith-Plandent-Division-for-Distribution-of-AirocideR-to-Dental-Providers

News Provided by ACCESSWIRE via QuoteMedia

AUVI:NSD
The Conversation (0)

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Acne Vulgaris Treatment PrARAZLO Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% ww), is now available to patients through BC PharmaCare, the public drug program of British Columbia

ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the appointment of international Contract Research Organization (CRO), Lindus Health, as a key partner for its U.S. clinical trials program.

Keep reading...Show less

Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto. A copy of the presentation will be available at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
{{ sections }}

Latest Press Releases

Related News

×